WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013148966) TRANSMUCOSAL DELIVERY OF ENGINEERED POLYPEPTIDES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/148966    International Application No.:    PCT/US2013/034300
Publication Date: 03.10.2013 International Filing Date: 28.03.2013
IPC:
A61K 38/16 (2006.01), A61K 38/17 (2006.01), A61P 17/00 (2006.01)
Applicants: AMYLIN PHARMACEUTICALS, LLC [US/US]; 9360 Towne Centre Drive San Diego, California 92121 (US).
ASTRAZENECA PHARMACEUTICALS LP [US/US]; 1800 Concord Pike Wilmington, Delaware 19897 (US).
REN, Steven, Shijun [CN/US]; (US) (US only).
JIN, Li [US/US]; (US) (US only)
Inventors: REN, Steven, Shijun; (US).
JIN, Li; (US)
Agent: KOERBER, Steven, C.; Kilpatrick Townsend & Stockton LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111 (US)
Priority Data:
61/616,961 28.03.2012 US
Title (EN) TRANSMUCOSAL DELIVERY OF ENGINEERED POLYPEPTIDES
(FR) ADMINISTRATION TRANSMUQUEUSE DE POLYPEPTIDES GÉNÉTIQUEMENT MODIFIÉS
Abstract: front page image
(EN)Formulations are provided that comprise compounds having inter alia good duration of action, high potency and/or convenient dosing regimens, and a permeation enhancer for transmucosal administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. The pharmaceutical compositions provided are suitable for methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, short bowel syndrome, Parkinson's disease, cardiovascular disease, and other and disorders of the central nervous system.
(FR)L'invention concerne des formulations qui comprennent des composés ayant entre autre une bonne durée d'action, une haute activité et/ou des régimes posologiques pratiques, et un stimulateur de perméation pour une administration transmuqueuse. Les composés sont des polypeptides génétiquement modifiés qui incorporent un domaine de liaison à l'albumine en combinaison avec un ou plusieurs polypeptides biologiquement actifs. Les compositions pharmaceutiques de l'invention sont appropriées pour des méthodes de traitement de maladies et de troubles comprenant l'obésité et le surpoids, le diabète, la dyslipidémie, l'hyperlipidémie, la maladie d'Alzheimer, la stéatose hépatite, le syndrome de l'intestin court, la maladie de Parkinson, une maladie cardiovasculaire et d'autres maladies, et des troubles du système nerveux central.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)